Sharad Sathyan, MD
Nephrology · Bloomfield, CTNPI 1508065681
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Amgen at 51.5% of the total. 2025 is the largest year on record at $34,646, more than ten times the $175 reported in 2019. Among nephrology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $255.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$19K
- Travere Therapeutics, Inc.$16K
- Novartis$307
- Novo Nordisk$292
- Baxter Healthcare$267
- Medtronic$229
- plus $1K from 15 others
Across 203 payments — averaging $13,851 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$2.7M
- AstraZeneca$95K
- Astrazeneca UK Limited$39K
What the payments were for
- Consulting fees$11,62532%
- Speaking & faculty fees$17,02547%
- Travel & lodging$4,31512%
- Food & beverage$3,55410%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 42 | $18,858 |
| Travere Therapeutics, Inc. | 39 | $15,599 |
| Novartis | 4 | $307 |
| Novo Nordisk | 8 | $292 |
| Baxter Healthcare | 3 | $267 |
| Medtronic | 3 | $229 |
| Aurinia Pharma U.S., Inc. | 7 | $183 |
| Otsuka America Pharmaceutical, Inc. | 3 | $145 |
| Akebia Therapeutics Inc | 6 | $137 |
| Vifor Pharma, Inc. | 6 | $108 |
| Mallinckrodt Hospital Products Inc. | 3 | $85 |
| GSK | 2 | $57 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $56 |
| Bayer | 3 | $53 |
| Fresenius USA Marketing, Inc. | 2 | $46 |
| Calliditas Therapeutics US Inc. | 2 | $44 |
| AstraZeneca | 2 | $36 |
| OPKO Pharmaceuticals, LLC | 2 | $34 |
| Lilly USA, LLC | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$18,184
- Filspari$9,235
- Fabhalta$225
- SYMPLICITY G3$141
- Renal - Non Product Related$125
- Ozempic$120
How this compares
$36,592 in reported general payments places this provider in the 90th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 20 | $905,845 |
| FarxigaDapagliflozin Propanediol | 182 | $198,071 |
| VelphoroSucroferric Oxyhydroxide | 34 | $130,622 |
| KerendiaFinerenone | 109 | $114,101 |
| LupkynisVoclosporin | 11 | $112,069 |
| JardianceEmpagliflozin | 93 | $88,059 |
| VeltassaPatiromer Calcium Sorbitex | 39 | $66,146 |
| RayaldeeCalcifediol | 26 | $31,487 |
| AuryxiaFerric Citrate | 23 | $28,830 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $17,025 |
| Sevelamer Carbonate | 54 | $13,647 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 42 | $9,072 |
| Calcitriol | 211 | $4,969 |
| ProsolParenteral Amino Acid 20% No.1 | 26 | $4,236 |
| Potassium Chloride | 31 | $3,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $18,858 | $905,84520 claims |
| AstraZenecaFarxiga, Lokelma | $36 | $215,096202 claims |
| Fresenius USA Marketing, Inc.Velphoro | $46 | $130,62234 claims |
| BayerKerendia | $53 | $114,101109 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $183 | $112,06911 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $34 | $31,48726 claims |
| Akebia Therapeutics IncAuryxia | $137 | $28,83023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 nephrology providers in Connecticut.
Other nephrology in Bloomfield
- Ari GellerBloomfield$209K
- Robert AlpernNew Haven$4.9M
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- David SimonOrange$59K
- Ladan GolestanehNew Haven$54K
- Jay GinsbergUncasville$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.